"The Once A Day Protease Inhibitor Regimens"

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients enrolled at a county clinic

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Atazanavir	Atazanavir/ritonavir (300mg/100mg) once daily
Fosamprenavir	Fosamprenavir/ritonavir (1400mg/100mg) once daily

Participant Flow:   Overall Study

	Atazanavir	Fosamprenavir
STARTED	39	37
COMPLETED	21	15
NOT COMPLETED	18	22
Lost to Follow-up	12	17
Death	4	2
Lack of Efficacy	1	2
no medicaiton dispensed	1	1

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Atazanavir	No text entered.
Fosamprenavir	No text entered.
Total	Total of all reporting groups

Baseline Measures

	Atazanavir	Fosamprenavir	Total
Overall Participants Analyzed  [Units: Participants]	39	37	76
Age  [Units: Participants]
<=18 years	0	0	0
Between 18 and 65 years	38	33	71
>=65 years	1	4	5
Age  [Units: Years] Mean (Standard Deviation)	48  (9.7)	48  (10)	48  (10)
Gender  [Units: Participants]
Female	11	9	20
Male	28	28	56
Region of Enrollment  [Units: Participants]
United States	39	37	76

1.  Primary:

Proportion of Patient With Viral Load Less Than 400 Copies/mL   [ Time Frame: 24 weeks ]

2.  Secondary:

CD4 Cell Count Change From Baseline During Treatment.   [ Time Frame: 24 weeks. ]

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
High porportion of subject did not complete the study.